FibroGen, Inc. (FGEN)
Market Cap | 2.29B |
Revenue (ttm) | 122.91M |
Net Income (ttm) | -361.56M |
Shares Out | 93.96M |
EPS (ttm) | -3.89 |
PE Ratio | n/a |
Forward PE | 61.35 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,114,533 |
Open | 23.60 |
Previous Close | 23.60 |
Day's Range | 23.44 - 24.58 |
52-Week Range | 7.81 - 24.58 |
Beta | 0.72 |
Analysts | Buy |
Price Target | 17.95 (-26.4%) |
Earnings Date | Feb 27, 2023 |
About FGEN
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human mon... [Read more]
Financial Performance
In 2021, FibroGen's revenue was $235.31 million, an increase of 33.46% compared to the previous year's $176.32 million. Losses were -$290.02 million, 53.2% more than in 2020.
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for FGEN stock is "Buy." The 12-month stock price forecast is $17.95, which is a decrease of -26.40% from the latest price.
News

FibroGen to Present at SVB Securities Global Biopharma Conference
SAN FRANCISCO, Feb. 02, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a virtual fireside chat at the SVB Se...

FibroGen to Participate at Bank of America 2022 Biotech SMID Cap Virtual Conference
SAN FRANCISCO, Nov. 28, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the Bank of Americ...

FibroGen (FGEN) Reports Q3 Loss, Misses Revenue Estimates
FibroGen (FGEN) delivered earnings and revenue surprises of -18.07% and 53.74%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

FibroGen Reports Third Quarter 2022 Financial Results
SAN FRANCISCO, Nov. 07, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the third quarter 2022 and provided an update on the company's recent developments.

FibroGen Announces $50 Million Royalty Monetization Financing with NovaQuest Capital Management
SAN FRANCISCO, Nov. 07, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced a royalty monetization financing with NovaQuest Capital Management (NovaQuest) that will result in procee...

FibroGen to Participate at Stifel 2022 Healthcare Conference
SAN FRANCISCO, Nov. 01, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the Stifel 2022 He...

Earnings Preview: FibroGen (FGEN) Q3 Earnings Expected to Decline
FibroGen (FGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

FibroGen to Report Third Quarter 2022 Financial Results
SAN FRANCISCO, Oct. 24, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its third quarter 2022 financial results on Monday, November 7 after the market close. FibroGen will also c...

7 Unknown Biotech Stocks That Could Rocket in 2023
Investing in early-stage or unknown biotech stocks can be likened to investing in cryptocurrency projects. If the project developments are positive, returns can be multi-folds in a short time.

FibroGen Announces Completion of Patient Enrollment in MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients with Lower Risk Transfusion-Dependent Myelodysplastic Syndromes (MDS)
- 141 MDS Patients Enrolled - - Topline Data Anticipated 1H:2023 -

FIBROGEN INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Provides Update of its Investigation of the Officers and Directors of FibroGen, Inc. - FGEN
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), provides an update to KSF's continued inves...

FibroGen (FGEN) Reports Q2 Loss, Misses Revenue Estimates
FibroGen (FGEN) delivered earnings and revenue surprises of 17.02% and 18.57%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

FibroGen Reports Second Quarter 2022 Financial Results
SAN FRANCISCO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the second quarter 2022 and provided an update on the company's recent developments.

FibroGen to Report Second Quarter 2022 Financial Results
SAN FRANCISCO, July 25, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its second quarter 2022 financial results on Monday, August 8 after the market close. FibroGen will also co...

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating FibroGen, Inc.
Wilmington, Delaware--(Newsfile Corp. - July 20, 2022) - Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of FibroGen, Inc. (NASDAQ: FGEN) on behalf of stockhol...

FibroGen to Participate at William Blair Biotech Focus Conference 2022
SAN FRANCISCO, July 01, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the William Blair ...

FibroGen Announces Completion of Patient Enrollment in LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Duchenne Muscular Dystrophy
- 73 Ambulatory DMD Patients Enrolled - - Topline Data Anticipated 2H:2023 -

FIBROGEN INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of FibroGen, Inc. - FGEN
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigat...

FibroGen to Present at Jefferies Healthcare Conference
SAN FRANCISCO, May 26, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the Jefferies Healt...

FibroGen (FGEN) Reports Q1 Loss, Tops Revenue Estimates
FibroGen (FGEN) delivered earnings and revenue surprises of 19.05% and 120.72%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

FibroGen Reports First Quarter 2022 Financial Results
SAN FRANCISCO, May 09, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the first quarter 2022 and provided an update on the company's recent developments.

SHAREHOLDER ALERT: Rigrodsky Law, P.A. is Investigating FibroGen, Inc.
Wilmington, Delaware--(Newsfile Corp. - May 5, 2022) - Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of FibroGen, Inc. (NASDAQ: FGEN) on behalf of stockholde...

FibroGen (FGEN) Expected to Beat Earnings Estimates: Should You Buy?
FibroGen (FGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

FibroGen to Report First Quarter 2022 Financial Results
SAN FRANCISCO, April 25, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its first quarter 2022 financial results on Monday, May 9 after the market close. FibroGen will also condu...

FibroGen Announces Completion of Patient Enrollment in ZEPHYRUS-1, a Phase 3 Clinical Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis
- 356 IPF Patients Enrolled -